



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/04, 38/10, C07K 7/08, 14/00, 4/12	A1	(11) International Publication Number: WO 98/53843 (43) International Publication Date: 3 December 1998 (03.12.98)
<p>(21) International Application Number: PCT/US97/11707</p> <p>(22) International Filing Date: 30 May 1997 (30.05.97)</p> <p>(71) Applicant (for all designated States except US): TANOX BIOSYSTEMS, INC. [US/US]; 10301 Stella Link Road, Houston, TX 77025-5497 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): CHEN, Alex [US/US]; LaJolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121 (US). CHANG, Tse, Wen [US/-]; College of Life Sciences, National Tsing Hua University, Hsin-Chu (TW).</p> <p>(74) Agent: MIRABEL, Eric, P.; Tanox Biosystems, Inc., 10301 Stella Link Road, Houston, TX 77025-5497 (US).</p>		<p>(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: INHIBITION OF ANTIGEN-SPECIFIC IgE PRODUCTION BY ANTIGEN COUPLED TO MEMBRANE IgE PETIDE</p> <p>(57) Abstract</p> <p>Disclosed is the use of the extracellular portion of the membrane-bound domain of the ϵ chain (from IgE) designated <i>migis-ϵ</i> peptides, or fragments or derivatives thereof, conjugated with antigen(s), for use in desensitization to such conjugated antigen(s). Two different isoforms of the <i>migis-ϵ</i> peptide are disclosed. These conjugates are administered to suppress IgE specific for the antigen of the conjugate, and therefore, suppress the allergic response to that antigen.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5 **Inhibition of Antigen-Specific IgE Production by Antigen
 Coupled to Membrane IgE Peptide**

Field of the Invention

 The invention relates to use of peptide-antigen conjugates to suppress IgE
10 production in an antigen-specific manner, to desensitize a subject to the antigen
 of the conjugate.

Background of the Invention

 Immunoglobulins consist of two peptide chains, a heavy chain and a light
 chain. There are five classes of immunoglobulins: IgG, IgM, IgA, IgD, and IgE.
15 In IgE, the heavy chain is designated as the ϵ chain.

 There are two forms of immunoglobulins: the secreted and the membrane-
 bound form. The membrane-bound form differs from the secreted form in that
 the former has a membrane-anchoring peptide extending from the C terminus of
 the ϵ chain. This membrane-anchoring peptide affixes the membrane-bound
20 immunoglobulin to the cell membrane surface.

 Membrane-anchoring peptides can be divided into three segments in terms
 of locations in relation to the plasma membrane. The middle segments have
 hydrophobic and uncharged amino acid residues, suggesting that they are in the
 membrane lipid bilayer. The C-terminal hydrophilic segments and have fewer
25 amino acid residues, suggesting that they are intracellular. The segments toward
 the N-termini are highly acidic and hydrophilic, suggesting that they are on the
 extracellular surface of the plasma membrane.

2

The extracellular segments of these peptides are unique for different isotypes. Therefore, the extracellular segment of the ϵ chain membrane anchoring peptide forms, in whole or in part, an epitope unique to the B cells which produce IgE. However, this membrane-bound immunoglobulin isotype specific
5 ("*migis*") extracellular epitope is not present on secreted, soluble IgE because only the immunoglobulin which is bound to the surface of B cells contains the membrane anchoring peptide as part of its heavy chain.

The immediate-type hypersensitivities, such as extrinsic asthma, hay fever, and allergic responses to certain foods or drugs, are mediated primarily by IgE.
10 In an IgE-mediated allergic response, the allergen binds to the IgE which is bound to receptors on the surface of mast cells and basophilic leukocytes (basophils). The binding of the allergen causes crosslinking of the surface IgE molecules and hence the underlying receptors for the Fc portion of IgE (Fc ϵ R), thereby triggering the release of pharmacologic mediators such as histamine, the slow-
15 reacting substance of anaphylaxis (SRA), and serotonin. The release of these mast cell and basophil products causes the pathological reactions and symptoms of allergy.

IgE is secreted by a particular class of B cells, which also express IgE on their surface. In individuals sensitized to specific allergens, the allergen-specific
20 IgE is continuously produced by these B cells. Nevertheless, individuals who have no secreted IgE in their systems (and no IgE-producing B cells) appear to

live normally, indicating that IgE is not essential in the immune response. IgE may, however, be useful in fighting infection by parasites.

It seems, therefore, that suppressing or depleting IgE would be a viable therapy for allergic diseases. Depleting IgE which binds to particular antigens
5 would prevent those antigens from reacting to cause an allergic reaction.

Administration of antigens to reduce an allergic reaction on subsequent exposure to the antigens is known as desensitization. It is a widely accepted method of therapy for allergic diseases.

Summary of the Invention

10 The invention includes *migis- ϵ* peptides, or fragments or derivatives thereof, conjugated with antigens, or fragments or derivatives thereof. In the invention, these conjugates are administered to suppress IgE specific for the antigen of the conjugate, and therefore, suppress the allergic response to that antigen. Treatment with these conjugates will not result in IgE-anti-IgE
15 complexes because the *migis- ϵ* sequence is absent in the secretory IgE, and antibodies generated against the *migis- ϵ* sequence, therefore, will not bind to the secretory IgE.

The invention also includes a number of variations and derivatives. There are two different isoforms of IgE present in humans, and either, or fragments or
20 derivatives of either, can be conjugated to antigens and administered to reduce the IgE against that antigen. To reduce the antigen-specific IgE in mammals other than humans, one would use the *migis- ϵ* sequence from such mammal, conjugated

with an antigen of interest. This could be an effective veterinary treatment for allergic reactions caused by certain allergens such as flea allergy dermatitis in dogs, which results from flea bites.

Description of Making and Using the Invention

5 Immunization of mice with conjugates of an antigen and the mouse *migis-ε* peptide induced IgE-nonresponsiveness to that antigen on subsequent challenge with it. Rational extrapolation provides that immunization of humans or other mammals with a corresponding *migis-ε* peptide/antigen conjugate would induce IgE-nonresponsiveness on subsequent challenge with that antigen. This would allow
 10 induction of IgE-nonresponsiveness to common allergens such as ragweed pollen, dust mite feces, cat and dog dander and saliva, or other common allergens. This would provide an effective method of allergen-specific desensitization.

For humans, two different isoforms of the *migis-ε* segment are known. The first is represented by amino acid numbers 4 to 18 of SEQ ID NO.:1 (Glu
 15 Leu Asp Val Cys Val Glu Glu Ala Glu Gly Glu Ala Pro Trp), and the second has this amino acid sequence 4 to 18 of SEQ ID NO.:1 spliced to the C terminal end of amino acid numbers 4 to 55 of SEQ ID NO.:2 (Gly Leu Ala Gly Gly Ser Ala Gln Ser Gln Arg Ala Pro Asp Arg Val Leu Cys His Ser Gly Gln Gln Gln Gly Leu Pro Arg Ala Ala Gly Gly Ser Val Pro His Pro Arg Cys His Cys Gly Ala Gly
 20 Arg Ala Asp Trp Pro Gly Pro Pro). Fragments, variant sequences, or derivatives, of either of these segments could also be used in the conjugates of the

5

invention. These segments could also be extended with additional amino acids or other moieties and used in the conjugates of the invention.

It is also possible to express conjugates including either isoform (or fragments or derivatives thereof) as fusion proteins, including the allergen(s) of
5 interest. This would be a desirable production method for most peptide allergens. The invention also includes the nucleotide sequences for such fusion proteins, *i.e.*, an isoform with an allergen, as well as vectors and host cells including such nucleotide sequences.

The conjugates of the invention are preferably administered intravenously,
10 subcutaneously, or intramuscularly, with an appropriate adjuvant. The dosages and administration regimen can be readily extrapolated from the animal data presented below.

Because of alternative mRNA splicings, there are two different nucleotide sequences which encode for peptides in the membrane anchoring region of human
15 ϵ chain. The deduced amino acid sequences encoded by these two nucleotide sequences are also different, indicating that there are two different isoforms of the human ϵ chain membrane anchoring peptide.

The deduced amino acid sequence of isoform I shows that it has 67 amino acid residues, and a 15 amino acid peptide segment toward the N-terminus (SEQ
20 ID NO:1). This 15 amino acid segment is proposed to be extracellular and to form, entirely or in-part, the *migis- ϵ* peptide. Isoform II has 119 amino acid residues, 67 of which are towards the N terminus and form the proposed

extracellular *migis-ε* segment (SEQ ID NO:2). Either isoform, or fragments or derivatives thereof, is appropriate for coupling to an antigen for use in the treatment method of the invention.

Example - Animal Model

- 5 Studies in mice have shown that a conjugate with an antigen and a *migis-ε* peptide can be a valuable therapeutic approach for desensitization to the antigen. These studies are described below.

Migis-ε peptide was selected from the mouse IgE genomic sequence, and had the sequence: Glu Leu Asp Ile Gln Asp Leu Cys Ile Glu Glu Val Glu Gly
10 Glu Glu Leu Glu Glu Leu (SEQ ID NO.: 3). Secretory IgE peptides with some of the sequences from the CH ϵ 1 to CH ϵ 4 domains were also prepared. They had the sequences: Thr Thr Ser Gln Val Thr Ser Trp Gly Lys Ser Ala Lys Asn Phe Thr Cys His Val Thr (SEQ ID NO.: 4) (residue numbers 190-210 of CH ϵ 1); Gly Val Asp Tyr Leu Ala His Thr Arg (SEQ ID NO.: 5) (residue numbers 316-324
15 of CH ϵ 2); Pro Leu Asp Leu Tyr Gln Asn Gly Ala Cys (SEQ ID NO.: 6) (residue numbers 343-351 of CH ϵ 3). IgE peptides at 5 mg/ml were mixed with insulin B chain, BSA, KLH respectively, at 2 mg/ml in equal volumes to which glutaraldehyde was added at a final 0.05%, incubated at 25°C for 4 hr, and dialyzed. Monoclonal rat anti-mouse IgE antibodies EM 95 and BF815 were
20 employed for the total IgE assay. Biotinylated rat anti-mouse kappa was obtained from Zymed (San Francisco, CA).

Eight week old female BALB/c mice were obtained from the Jackson Laboratory (Bar Harbor, ME). Mice were grouped and were treated with *migis- ϵ* coupled to protein carriers. Sera were collected on day seven after the last immunization. Antigen-specific IgE was assessed by the passive cutaneous
5 anaphylactic (PCA) skin test.

An anti-*migis- ϵ* assay was performed as follows. 50 μ l *migis- ϵ* -BSA at 10 μ g/ml were coated onto 96-well plate at 37°C for 1 hour. The plates were washed, blocked with Blotto, and added with 50 μ l serum samples at appropriate dilutions. The plates were washed, incubated with biotinylated goat anti-mouse
10 IgG or IgG subclasses, at 1 μ g/ml for 1 hour at room temperature, washed, added with SA-AP, substrate, and read at 414 nM.

A total IgE sandwich assay was performed as follows. 96-well plates were coated with 50 μ l MAb anti- ϵ , EM95, at 10 μ g/ml overnight at 4°C, washed, blocked, added with sera at appropriate dilutions, biotinylated MAb anti-
15 ϵ , BF815 was added, and plates developed as above.

An anti-IgE assay was performed as follows. Anti-NP IgE (lambda, ϵ) was used to coat the 96-well plates at 10 μ g/ml overnight at 4°C. The plates were washed and blocked. Sera were added at appropriate dilutions, washed, followed by biotinylated rat anti-mouse kappa light chain, and developed as
20 above.

migis- ϵ protein administered in complete and incomplete Freund's adjuvant (CFA/ICFA) inhibited IgE responses to the carrier protein. Adult BALB/c mice

were immunized five times i.p. with *migis- ϵ* -KLH (keyhole limpet hemocyanin) conjugates in CFA/ICFA, or in alum. Anti-KLH IgE responses were assessed in individual mice. A normal magnitude of anti-KLH IgE responses was observed in mice immunized i.p. with 10 μ g KLH in CFA/ICFA, or in alum.

- 5 In contrast, mice treated with 1 μ g or 10 μ g *migis- ϵ* -KLH in CFA/ICFA exhibited profoundly suppressed KLH specific IgE responses.

Migis- ϵ conjugated antigen did not affect antigen-specific IgG responses to the carrier. Comparable anti-KLH IgG1 responses were observed in KLH or *migis- ϵ* -KLH immunized mice, while alum favored antigen-specific IgG1
10 production over CFA/ICFA. Higher levels of anti-*migis- ϵ* of IgG1 subclass were observed in mice immunized with *migis- ϵ* -KLH in alum. In contrast, anti-KLH and anti-*migis- ϵ* of IgG2a and IgG2b subclasses were present in higher concentrations in mice immunized with *migis- ϵ* -KLH in CFA/ICFA. However, suppression of anti-KLH IgE responses appeared not directly correlated with the
15 levels of different subclasses of anti-*migis- ϵ* antibodies. Although anti-KLH IgE was suppressed in *migis- ϵ* -KLH treated mice, total IgE levels appeared to be normal in mice immunized with *migis- ϵ* -KLH emulsified in CFA/ICFA.

To ascertain that suppression of KLH responses was not due to alteration of protein carriers by chemical coupling, synthetic peptides corresponding to the
20 CHe1 to CHe4 domains, as well as insulin B chain (InB), were coupled to KLH by glutaraldehyde under similar conditions. Comparable magnitude of anti-KLH IgE responses was observed in mice immunized with KLH coupled to SEQ ID

9

NOS:4 to 6 or Insulin B chain in CFA/ICFA, whereas anti-KLH IgE responses were suppressed in mice treated with *migis- ϵ* -KLH.

Suppression of IgE responses to *migis- ϵ* conjugated proteins did not affect a concomitant unrelated antigenic challenge. To examine whether *migis- ϵ* -KLH
5 treatment may suppress IgE responses to an unrelated antigen, mice were pretreated with 1 to 50 μ g *migis- ϵ* -KLH in CFA/ICFA, or with 10 μ g *migis- ϵ* -KLH in CFA twice, followed by a challenge with *migis- ϵ* -KLH along with OVA in ICFA, and further boosted with OVA/*migis- ϵ* -KLH in ICFA twice. KLH administered in CFA/ICFA, inhibited IgE responses against the KLH to which
10 *migis- ϵ* was coupled, but did not inhibit IgE responses against an unrelated OVA antigenic challenge. In contrast, mice treated with glutaraldehyde-modified KLH from 1 to 50 μ g in CFA/ICFA exhibited normal levels of anti-KLH, and anti-OVA IgE responses.

To test whether suppression of *migis- ϵ* -KLH may be extended to other
15 *migis- ϵ* conjugated antigens, BALB/c mice were injected with 20 μ g soluble *migis- ϵ* -BGG or glutaraldehyde modified BGG (GA-BGG) subcutaneously, or intraperitoneally. Mice were then challenged with *migis- ϵ* -BGG plus OVA, or BGG plus OVA in alum. Mice treated with soluble *migis- ϵ* -BGG via either route, failed to elicit anti-BGG IgE when challenged with *migis- ϵ* -BGG or BGG in alum,
20 whereas anti-OVA IgE responses in these mice were normal. As a control, treatment with GA-BGG via either route did not affect subsequent anti-BGG or anti-OVA IgE responses.

10

Moreover, *migis-ε* conjugated BGG did not affect anti-BGG IgG responses. Comparable anti-BGG or anti-OVA IgG responses were observed in mice treated with *migis-ε*-BGG and GA-BGG. Anti-*migis-ε* IgG was not detectable in mice treated with soluble *migis-ε*-BGG. *migis-ε*-BGG treatment did
5 not augment the production of anti-IgE nor modulate the levels of total IgE levels. Moreover, total IgE as well as basal levels of anti-IgE antibodies were also comparable in mice treated with *migis-ε*-BGG or BGG as control.

Thus, it can be seen that inhibition of antigen-specific IgE production can be achieved by treatment with *migis-ε* conjugated antigens. The following were
10 observed: a) Inhibition of anti-KLH and anti-BGG IgE, but not IgG responses was observed in mice treated with soluble or *migis-ε*-conjugated protein emulsified in CFA/ICFA. b) Inhibition was observed in IgE responses to *migis-ε* conjugated carrier protein, but not toward an unrelated antigen. c) Inhibition of antigen-specific IgE was not correlated with levels of anti-*migis-ε* or anti-IgE
15 antibodies; d) total IgE levels remained comparable among mice treated with *migis-ε* conjugated antigens and native or glutaraldehyde-modified carrier antigen as control.

If conjugates were designed for use in humans, with one of the isoforms or a fragment or derivative thereof, as shown in SEQ ID NOS.: 1 and 2,
20 conjugated with an antigen, the same results would be expected. That is, one would expect to see: a) inhibition of antigen-specific IgE, but not IgG responses; b) no inhibition of IgE responses to unrelated, unconjugated antigens; c) no

11

correlation between inhibition of antigen-specific IgE and levels of anti-*migis-ε* or anti-IgE antibodies; d) total IgE levels would remain comparable among subjects treated with *migis-ε* conjugated antigens and those exposed to the native antigen. This would be an effective method of desensitizing human subjects to
5 allergens.

The terms, expressions and examples herein are exemplary only and not limiting, and those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. All such equivalents are intended to be
10 encompassed by the following claims.

SEQUENCE LISTING

- (1) General Information:
- (i) Applicant: Chen, Sway-Shen Alex; Chang, Tse Wen
- (ii) Title of Invention: Inhibition of Antigen-Specific IgE Production by Antigen
- 5 Coupled to Membrane IgE Peptide
- (iii) Number of Sequences: 6
- (iv) Correspondence Address:
- (A) Addressee: Tanox Biosystems, Inc.
- (B) Street: 10301 Stella Link Rd.
- 10 (C) City: Houston
- (D) State: Texas
- (E) Country: USA
- (F) Zip: 77025
- (v) Computer Readable Form:
- 15 (A) Medium Type: Diskette, 3.5 inch
- (B) Computer: IBM PS/2
- (C) Operating System: DOS 3.30
- (D) Software: Wordperfect 5.1
- (vi) Current application data:
- 20 (A) Application Number:
- (B) Filing Date:
- (C) Classification:
- (vii) Prior Application Data:
- (A) Application Number:
- 25 (B) Filing Date:
- (viii) Attorney/Agent Information:
- (A) Name: Mirabel, Eric P.
- (B) Registration Number: 31,211
- (C) Reference/Docket Number: TNX97-2-PCT
- 30 (ix) Telecommunication Information:
- (A) Telephone: (713) 664-2288
- (B) Telefax: (713) 664-8914
- (2) Information for SEQ ID NO:1:
- (i) Sequence Characteristics:
- 35 (A) Length: 216 nucleotides
- (B) Type: nucleic acid
- (C) Strandedness: double stranded
- (D) Topology: linear
- (xi) Sequence Description: SEQ ID NO:1:
- 40

13

	GTA	AAT	CCC	GAG	CTG	GAC	GTG	TGC	GTG	27
	Val	Asn	Pro	Glu	Leu	Asp	Val	Cys	Val	
	1				5					
5	GAG	GAG	GCC	GAG	GGC	GAG	GCG	CCG	TGG	ACG 57
	Glu	Glu	Ala	Glu	Gly	Glu	Ala	Pro	Trp	Thr
	10				15					
10	TGG	ACC	GGC	CTC	TGC	ATC	TTC	GCC	GCA	CTC 87
	Trp	Thr	Gly	Leu	Cys	Ile	Phe	Ala	Ala	Leu
	20				25					
15	TTC	CTG	CTC	AGC	GTG	AGC	TAC	AGC	GCC	GCC 127
	Phe	Leu	Leu	Ser	Val	Ser	Tyr	Ser	Ala	Ala
	30				35					
20	CTC	ACG	CTC	CTC	ATG	GTG	CAG	CGG	TTC	CTC 157
	Leu	Thr	Leu	Leu	Met	Val	Gln	Arg	Phe	Leu
	40				45					
25	TCA	GCC	ACG	CGG	CAG	GGG	AGG	CCC	CAG	ACC 187
	Ser	Ala	Thr	Arg	Gln	Gly	Arg	Pro	Gln	Thr
	50				55					
30	TCC	CTC	GAC	TAC	ACC	AAC	GTC	CTC	CAG	CCC 207
	Ser	Leu	Asp	Tyr	Thr	Asn	Val	Leu	Gln	Pro
	60				65					
35	CAC	GCC	TAG							216
	His	Ala								
	70									

(2) Information for SEQ ID NO:2:

(i) Sequence Characteristics:

35 (A) Length: 166 nucleotides

(B) Type: nucleic acid

(C) Strandedness: double stranded

(D) Topology: linear

(xi) Sequence Description: SEQ ID NO:2:

40

GTA	AAT	CCC	GGG	CTG	GCT	GGC	GGC	TCC	GCG	30
Val	Asn	Pro	Gly	Leu	Ala	Gly	Gly	Ser	Ala	
1				5					10	

45	CAG	TCC	CAG	AGG	GCC	CCG	GAT	AGG	GTG	CTC	60
	Gln	Ser	Gln	Arg	Ala	Pro	Asp	Arg	Val	Leu	
				15						20	

50

14

- TGC CAC TCC GGA CAG CAG CAG GGA CTG CCG 90
 Cys His Ser Gly Gln Gln Gln Gly Leu Pro
 25 30
- 5 AGA GCA GCA GGA GGC TCT GTC CCC CAC CCC 120
 Arg Ala Ala Gly Gly Ser Val Pro His Pro
 35 40
- 10 CGC TGC CAC TGT GGA GCC GGG AGG GCT GAC 150
 Arg Cys His Cys Gly Ala Gly Arg Ala Asp
 45 50
- TGG CCA GGT CCC CCA G 166
 Trp Pro Gly Pro Pro
 15 55
- (2) Information for SEQ ID NO:3:
 (i) Sequence Characteristics:
 (A) Length: 20
 20 (B) Type: amino acid
 (D) Topology: linear
 (xi) Sequence Description: SEQ ID NO:3:
- Glu Leu Asp Ile Gln Asp Leu Cys Ile Glu Glu Val
 25 1 5 10
- Glu Gly Glu Glu Leu Glu Glu Leu
 15 20
- 30 (2) Information for SEQ ID NO:4:
 (i) Sequence Characteristics:
 (A) Length: 20
 (B) Type: amino acid
 (D) Topology: linear
 35 (xi) Sequence Description: SEQ ID NO:4:
- Thr Thr Ser Gln Val Thr Ser Trp Gly Lys Ser Ala Lys
 1 5 10
- 40 Asn Phe Thr Cys His Val Thr
 15 20
- (2) Information for SEQ ID NO:5:
 (i) Sequence Characteristics:
 45 (A) Length: 9
 (B) Type: amino acid
 (D) Topology: linear
 (xi) Sequence Description: SEQ ID NO:5:

15

Gly Val Asp Tyr Leu Ala His Thr Arg
1 5

(2) Information for SEQ ID NO:6:

5 (i) Sequence Characteristics:

(A) Length: 10

(B) Type: amino acid

(D) Topology: linear

(xi) Sequence Description: SEQ ID NO:6:

10

Pro Leu Asp Leu Tyr Gln Asn Gly Ala Cys
1 5 10

What Is Claimed Is:

1. A conjugate comprising an antigenic molecule coupled to a peptide, said peptide including all of or a fragment or derivative of the *migis-ε* peptide.
2. The conjugate of claim 1 wherein said *migis-ε* peptide has the sequence of
5 amino acid numbers 4 to 18 of SEQ ID NO:1.
3. The conjugate of claim 1 wherein said *migis-ε* peptide has the sequence of amino acid numbers 4 to 55 of SEQ ID NO:2 with amino acid numbers 4 to 18 of SEQ ID NO:1 attached to its C terminal end, or the *migis-ε* peptide is a fragment of such peptide.
- 10 4. A method of desensitization to an antigenic molecule comprising immunizing with the conjugate of any of claims 1 to 3.
5. A method of reducing the amount of antigen-specific IgE comprising administering a conjugate comprising an antigen coupled to a peptide, said peptide including all of or a fragment or derivative of the *migis-ε* peptide.
- 15 6. The method of claim 5 wherein said peptide has the sequence of amino acid numbers 4 to 18 of SEQ ID NO:1.
7. The method of claim 5 wherein said peptide has the sequence of amino acid numbers 4 to 55 of SEQ ID NO:2 with amino acid numbers 4 to 18 of SEQ ID NO:1 attached to its C terminal end, or a fragment of such peptide.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/11707

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/04, 38/10; C07K 7/08, 14/00, 4/12

US CL : 530/324, 325, 326, 327, 328, 329, 387.1, 405

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/324, 325, 326, 327, 328, 329, 387.1, 405

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,254,671 A (CHANG) 19 October 1993, column 10, lines 3-9.	1
X	US 5,274,075 A (CHANG) 28 December 1993, columns 8-10.	1 and 5
X	US 5,281,699 A (CHANG) 25 January 1994, column 16, lines 16-23.	1

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

12 SEPTEMBER 1997

Date of mailing of the international search report

06 OCT 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

LAURIE SCHEINER

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/11707

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 2-4, 6 and 7
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

the claims are limited to specific sequence identifiers, however, a sequence disk was not submitted. In the absence of the sequences in computer readable form, claims 2-4, 6 and 7 are unsearchable.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.